NCT06773195View on ClinicalTrials.gov

A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

January 7, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2028

Conditions
Myelofibrosis
Interventions
DRUG

Ulixertinib

There are 3 planned dose levels of ulixertinib(450 mg BID, 300 mg BID, or 150 mg BID)

DRUG

Ruxolitinib

Ruxolitinib for 28 day cycles.

Trial Locations (9)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

11725

RECRUITING

Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack

44195

NOT_YET_RECRUITING

Cleveland Clinic, Cleveland

02114

NOT_YET_RECRUITING

Massachusetts General Hospital (Data Collection Only), Boston

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

Sponsors
All Listed Sponsors
collaborator

BioMed Valley Discoveries, Inc

INDUSTRY

collaborator

Incyte Corporation

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT06773195 - A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis | Biotech Hunter | Biotech Hunter